Aurobindo Pharma Limited (AUROPHARMA) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Aurobindo Pharma enters Q1 FY27 results following a quarter of significant currency tailwinds and strategic portfolio expansion, including the finalized acquisition of Lannett Company. Investors will look for clarity on whether these gains and the company's backward integration efforts can propel EBITDA margins toward the guided 21% threshold despite ongoing regulatory scrutiny at key injectable facilities.

Aurobindo Pharma Limited Q1 Results Date and Time

The board meeting is scheduled for August 05, 2026, to consider the Q1 FY27 financial results.

What to expect from Aurobindo Pharma Limited's Q1 FY27 results

Aurobindo's revenue is likely to see a significant reported boost from the 7-8% YoY INR depreciation, which management estimates provides a Rs. 100 Cr EBITDA benefit for every 1% of currency movement. While the US injectable business remains constrained by OAI classifications at Eugia Units I and III, the oral solid segment's momentum and the contribution of approximately 9 new launches per quarter are expected to support top-line growth. The Pen-G and 6-APA projects, which incurred over Rs. 200 Cr in losses during FY26, have turned positive EBITDA, providing a structural tailwind for the API segment. However, management must navigate rising raw material and solvent costs, which have increased 2.5-2.7x, potentially offsetting some of the currency-driven margin expansion. The upcoming call will focus on the reconciliation of these cost pressures against the FY27 guidance of EBITDA margins north of 21%.

Key Things To Watch

Performance vs Guidance Tracking: Tracking progress against key FY27 and open-ended strategic targets.

• EBITDA margin target of >21% for FY27 — watch Q1 trajectory against the 20.3% exit in Q4 FY26
• Minimum double-digit revenue growth (ex-gRevlimid) — FY26 growth was 9.5%
• US $2 billion revenue milestone — integration of Lannett expected to contribute ~$300 Mn annually

Regulatory Developments: Monitoring the impact of recent US FDA classifications on injectable supply.

• Eugia Units I and III OAI classifications — status of remediation and potential impact on new ANDA approvals
• Eugia Steriles inspection — update on the 5 observations from the June 2026 pre-approval inspection
• Eugia III reinspection — any progress on the timeline for resolving OAI status to restore injectable capacity

Strategic Initiatives: Integration and commercialization status of recent acquisitions and facilities.

• Lannett integration — initial revenue contribution and synergy timeline following the June 29, 2026 closing
• Khandelwal Laboratories deal — status of the Rs. 3,250 Mn acquisition and transfer of domestic business to Auropharm Ltd
• TheraNym biologics CMO — timeline for MSD product commercialization and initial revenue expectations

Operating metric trajectory: Key segment KPIs and production milestones.

• Pen-G production — sustaining the >10,000 MT run rate and impact of $25/kg MIP on API pricing
• US revenue — dollar-denominated performance excluding the impact of gRevlimid decline
• Europe revenue — monitoring for mid-to-high single-digit constant currency growth